Co-payment
|
N/A
|
+
|
Esposito1 [45] (US, OS, CD, R)
|
Multi-tier formulary (vs. 1- or 2-tiers)
|
0
|
+
|
Huskamp et al. [125] (US, NS, CD, R); Motheral and Fairman [28] (US, NS, CD, R)
|
Multi-tier formulary (vs. 1- or 2-tiers)
|
0
|
N/A
|
Gibson et al. [90] (US, NS, PD, R); Motheral and Henderson [63] (US, NS, CD, R)
|
Multi-tier formulary (vs. 1- or 2-tiers)
|
N/A
|
+
|
Kamal-Bahl and Briesacher [91] (US, OS, CD, R); Landsman et al. [65] (US, NS, TD, R);
|
Co-insurance
|
0
|
N/A
|
Liebowitz et al. [48] (US, ES, CD, R); Newhouse [49] (US, ES, CD, R)
|
Mixed system
|
+
|
N/A
|
Hong and Shepherd [46] (US, OS, CD, NR); Mortimer [47] (US, OS, CD, R)
|
Reference pricing (non-RP drugs)
|
+
|
N/A
|
Marshall et al. [42] (CA, NS, TD, R); McManus et al. [43] (AU, NS, TD, R); Narine et al. [44] (CA, NS, TD, NR)
|
Reference pricing (non-RP drugs)
|
N/A
|
+
|
Mabasa and Ma [39] (CA, NS, CS, NR)
|